Cannon.Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?. The American Journal of Cardiology . 2005Ray KK and Cannon CP: Early time to benefit with inten- sive statin treatment: Could it be the pleiotropic effects ? Am J Cardiol, 2005; 96 (suppl)...
Naming functions this way also has a benefit that these names will be removed during minification (when building for production), which automatically makes your bundle smaller with no extra effort. Alternatively, you can use thenameFn()utility, which simply attachesdisplayNameproperty to the function...
Rationalizing prescribing for older patients with multimorbidity: considering time to benefit. Drugs Aging. 2013;30(9):655-666.PubMedGoogle ScholarCrossref 7. Russell BJ, Rowett D, Abernethy AP, Currow DC. Prescribing for comorbid disease in a palliative population: focus on the use of lipid...
A lower threshold could increase treatment costs for less at-risk groups without significant health benefits, while a higher threshold may lead to undertreatment of patients who could benefit from statins. Despite their effectiveness, statins carry risks, notably the increased likelihood of developing ...
However, due to very limited data, further studies are necessary to confirm the real effects of phytosterols on lipid profile in SAMS patients as well as at which doses statin intolerant patients might benefit the most from phytosterols therapy (Table 7). Table 7. Phytosterols ClassLevelActive ...
This educational activity is intended to clarify the safety (and tolerability) of statins across multiple tissues (eg, skeletal muscle) and organ systems (eg, liver, kidney, nervous system) by evaluating the impact of statin-associated adverse events within a larger benefit:risk context. Upon co...
The decreased risk of dementia associated with statin use applied to diverse patient groups, remained independent of other cardiovascular medication use, intensified over time, was distinct from the risk of subsequent depression, and was not observed in patients after an ankle sprain. Conclusions and ...
Second, we extrapolated statin benefit for patients receiving treatment over the course of their lifetime, which is a commonly used assumption in CVD modeling studies.11 We did, however, assume long-term compliance rates of 50% and reduced treatment effects accordingly. Third, we did not ...
Time‐to‐event data were analysed using the Cox proportional hazards model, adjusted for confounders and compared the placebo and pravastatin groups. Results: A total of 5.804 subjects were included. In the placebo group, the highest risk group (high FIB‐4 and obesity) had a signific...
Not enough data exist to support local effects of systemic statin therapy, such as prevention of restenosis. For statin dosing, there is little increased benefit to intense therapy compared with the adverse effects, whereas moderate-dose therapy has significant benefits with very few adverse effects....